CLINICAL_TRIALS
trial_result
· 2024-10-16
Clinical Trial Update: Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) [Phase 2]
Summary
Phase 2 open-label study of alum-adjuvanted chikungunya virus-like particle vaccine PXVX0317 completed; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bavarian Nordic | Conditions: Chikungunya | Phase 2 | Status: COMPLETED | Results posted: 2024-10-16